Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically meaningful improvement however, zetomipzomib did not demonstrate a significant differentiation from the placebo. We will learn more from this study with additional deeper analysis in the near future.

Click here for more information

Leave a Reply

Your email address will not be published. Required fields are marked *